[Latest] Global CRISPR-based Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
View original at globenewswire.com[Latest] Global CRISPR-based Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) Austin, TX, USA, June 03, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a n…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The global CRISPR-based Gene Editing Market was valued at approximately USD 3.65 billion in 2024
60% confidenceTALEN and ZFN alternative genome editing technologies pose a competitive threat to CRISPR market share
60% confidenceEmerging markets are granting less regulatory friction to genome-edited crops than to traditional GMOs
60% confidenceIn Q1 2025, funding for agricultural gene editing startups surged to nearly double the amount received throughout all of 2024
60% confidenceIn March 2025, a CRISPR-based therapy received expanded orphan drug designation from the FDA for treating a rare genetic liver metabolic disorder
60% confidenceIn January 2025, an industry leader launched a fully automated CRISPR-based workstation that designs host organisms for enzyme production
60% confidenceMajor CRISPR players are enhancing precision gene editing via scalable platforms using automation, genomic cloud computing, and AI-generated guide RNAs
60% confidenceOff-target effects, ineffective delivery mechanisms, lack of global uniform regulations, and IP disputes are significant weaknesses limiting CRISPR commercial adoption
60% confidenceThe CRISPR-based Gene Editing Market is projected to grow to around USD 12.6 billion by 2034 at a CAGR of approximately 13.01% from 2025 to 2034
60% confidenceIn August 2025, China deployed the first in-house CRISPR-based Cas12-based infectious disease screening systems, achieving regional self-sufficiency
60% confidenceA new gene-editing firm opening its CRISPR facility in Massachusetts in February 2024 is expected to drive sharp growth in North American Cas enzyme production
60% confidenceThe CRISPR-based Gene Editing Market is expected to reach USD 4.10 billion in 2025
60% confidenceIn October 2024, Brazil launched national field trials of CRISPR-edited drought-resistant maize varieties, becoming the first country with a government-backed genome editing crop initiative
60% confidenceGermline editing ethical concerns, biosafety issues, regulatory uncertainty, and cybersecurity risks in digital genomics are looming threats to the CRISPR market
60% confidencePharmaceutical manufacturers have multiple personalized CRISPR clinical programs in progress for sickle cell and retinal diseases
60% confidence